Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

Inflamm Bowel Dis. 2004 Jan;10(1):28-31. doi: 10.1097/00054725-200401000-00004.

Abstract

Background: Inflammatory demyelinating disease of the central nervous system may be linked to anti-tumor necrosis factor alpha therapy.

Case history: A 19-year-old female with Crohn's ileocolitis developed right arm and leg numbness and right hand weakness 4 weeks after the initiation of infliximab. Neurologic examination confirmed upper and lower right extremity sensory and motor deficits. MRI examination of the head and thoracic cord showed multiple gadolinium-enhancing lesions with distribution and configuration most suggestive of multiple sclerosis or other demyelinating process. The infliximab therapy was immediately stopped and follow-up at 8 weeks revealed symptomatic improvement.

Conclusion: This case report describes the onset of a demyelinating process after the institution of infliximab therapy in a patient with Crohn's disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Crohn Disease / drug therapy*
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / diagnosis*
  • Demyelinating Diseases / pathology
  • Diagnosis, Differential
  • Female
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Hypesthesia / chemically induced
  • Hypesthesia / diagnosis
  • Hypesthesia / pathology
  • Infliximab
  • Magnetic Resonance Imaging
  • Medulla Oblongata / pathology
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab